Company News

BRIEF-Nuvo Pharmac reports Q2 loss per share of C$0.02 from cont ops

Aug 10 (Reuters) - Nuvo Pharmaceuticals Inc

* Nuvo Pharmaceuticals™ announces 2017 second quarter results

* Q2 loss per share c$0.02 from continuing operations

* Q2 revenue c$3.1 million versus c$8.1 million

* Nuvo Pharmaceuticals Inc - at quarter end, cash and short-term investments increased to $20.0 million with no debt

* Nuvo Pharmaceuticals Inc - reallocation of resources included reduction in size of primary care sales force that markets pennsaid 2% to physicians

* Nuvo Pharmaceuticals - has not yet seen negative impact from sales force reduction that might impact typical commercial bottle ordering patterns

* Nuvo Pharmaceuticals- expects horizon’s cost reallocation initiatives to also result in decrease in no. Of product samples horizon distributes to physicians

* Nuvo Pharmaceuticals Inc - reduction in sample product orders from horizon will have a negative impact on company’s future financial results Source text for Eikon: Further company coverage: